



# China Interferon Industry Report, 2016-2021

Apr.2017

## **STUDY GOAL AND OBJECTIVES**

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

## **REPORT OBJECTIVES**

- ◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- ◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- ◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

## **METHODOLOGY**

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

## **INFORMATION SOURCES**

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

## Abstract

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN- $\alpha$  is mainly suitable for curing hepatitis B and hepatitis C, while IFN- $\beta$  is the mainstream medicine for MS which sees a higher incidence in Europe and America than in Asia, so foreign countries usually adopt IFN- $\beta$  whereas clinical applications in China center on IFN- $\alpha$ .

China where liver diseases prevail has maintained the demand for interferon worth more than RMB4 billion in recent years, of which hepatitis B-use interferon accounts for over 60% of the entire interferon market. However, the hepatitis B-use interferon market rapidly shrank in 2016 under the impact of the expired patented drugs, the substitution of nucleoside drugs and other factors, resulting in the sharp year-on-year decline of 50.4% in the interferon revenue (RMB361 million) of Chinese sample hospitals in 2016; it was estimated that Chinese interferon market size hit about RMB2.22 billion in the whole 2016.

It is expected that Chinese interferon market will be hard to turn the declining situation around in the next few years. Both of the sluggish hepatitis B-use interferon market and the launch of DAAs drugs will make the hepatitis C-use interferon market suffer a crisis. At present, the overseas hepatitis C-use interferon market has been significantly affected by DAAs drugs and slumped. Although DAAs drugs are not available in China, more than 30 companies have filed for DAAs drugs and DAAs drugs are expected to be revealed in this country within 2 years, which will impact the domestic interferon market once again then.

In recent years, Chinese interferon market is mainly occupied by Roche and MSD, which seize more than 60% market share together, while local Chinese peers represented by Anke Biotechnology, Kawin Technology and Tri-Prime Gene grasp no more than 5% apiece. But in 2016, the contracted hepatitis B-use interferon market dramatically dragged down the combined market share of Roche and MSD to about 40%..


Interferon is mainly divided into ordinary interferon and long-acting interferon. Compared with ordinary interferon which should be injected three times a week, long-acting interferon is injected only once a week, which significantly reduces the patients' medication compliance with less side effect. Yet, Chinese long-acting interferon market has been monopolized by Roche and MSD which offer high prices.

On October 13, 2016, China's first long-acting interferon developed by Amoytop Biotech with independent intellectual property rights obtained the approval for the launch, breaking the monopoly of foreign enterprises. Moreover, Anke Biotechnology, Tri-Prime Gene, Chia Tai Tianqing and other companies are developing long-acting interferon. In the future, the competition in Chinese long-acting interferon market will prick up, which will further squeeze the market share of Roche and MSD.

The report mainly covers the following:

- ◆ Overview of China interferon industry, including development process, status quo, market size, market structure and competitive landscape;
- ◆ Analysis on China interferon market segments, especially in-depth analysis on market size, competitive landscape and prices of ordinary interferon and long-acting interferon;
- ◆ Analysis on the downstream market of China interferon industry, including status quo and development trend of hepatitis B, hepatitis C and pediatric markets;
- ◆ Operation and interferon business of 17 domestic and 2 foreign interferon enterprises;
- ◆ Summary and forecast.

## Interferon Market Share in China (by Company), 2016



Source: ResearchInChina

### **1 Overview**

- 1.1 Definition
- 1.2 Classification

### **2 Overview of China Interferon Industry**

- 2.1 Development Course
- 2.2 Status Quo
- 2.3 Market Size
- 2.4 Market Structure
- 2.5 Competitive Landscape

### **3 China Interferon Market Segments**

- 3.1 Ordinary Interferon
  - 3.1.1 Introduction
  - 3.1.2 Market Size
  - 3.1.3 Competitive Landscape
  - 3.1.4 Price Comparison
- 3.2 Long-acting Interferon
  - 3.2.1 Introduction
  - 3.2.2 Market Size
  - 3.2.3 Competitive Landscape
  - 3.2.4 Price Comparison

### **4 Downstream Market of China Interferon Industry**

- 4.1 Hepatitis B
  - 4.1.1 Introduction
  - 4.1.2 Therapy
  - 4.1.3 Interferon Hepatitis B Market Shrinks

### 4.1.4 Market Size

### 4.2 Hepatitis C

#### 4.2.1 Introduction

#### 4.2.2 Therapy

#### 4.2.3 The Launch of DAAs Drugs Impacts Chinese Interferon Hepatitis C Market

### 4.3 Pediatrics

### 4.4 Others

### **5 Major Chinese Enterprises**

#### 5.1 Anke Biotechnology

##### 5.1.1 Profile

##### 5.1.2 Operation

##### 5.1.3 Revenue Structure

##### 5.1.4 R & D and Investment

##### 5.1.5 Interferon Business

##### 5.1.6 Forecast and Prospect

#### 5.2 Tri-Prime Gene

##### 5.2.1 Profile

##### 5.2.2 Operation

##### 5.2.3 R & D

##### 5.2.4 Major Customers

##### 5.2.5 Interferon Business

##### 5.2.6 Forecast and Prospect

#### 5.3 Kawin Technology

##### 5.3.1 Profile

##### 5.3.2 Operation

##### 5.3.3 Revenue Structure

- 5.3.4 R & D and Investment
- 5.3.5 Major Customers
- 5.3.6 Interferon Business
- 5.3.7 Forecast and Prospect
- 5.4 Amoytop Biotech
  - 5.4.1 Profile
  - 5.4.2 Operation
  - 5.4.3 Interferon Business
- 5.5 Shenzhen Kexing Biotech
  - 5.5.1 Profile
  - 5.5.2 Interferon Business
- 5.6 Sinobioway Biomedicine
  - 5.6.1 Profile
  - 5.6.2 Interferon Business
- 5.7 3SBio
  - 5.7.1 Profile
  - 5.7.2 Operation
  - 5.7.3 Interferon Business
- 5.8 Harbin Pharmaceutical Group Bioengineering
  - 5.8.1 Profile
  - 5.8.2 Operation
  - 5.8.3 Interferon Business
- 5.9 Changchun Institute of Biological Products Co., Ltd.
  - 5.9.1 Profile
  - 5.9.2 Interferon Business
- 5.10 Zhejiang Hansheng Pharmaceutical Co., Ltd. of Beisheng Pharma
  - 5.10.1 Profile

- 5.10.2 Interferon Business
- 5.11 Others
  - 5.11.1 Hainan Xinmingda Biopharmaceutical Co., Ltd
  - 5.11.2 Beijing Yuance Pharmaceutical Co., Ltd.
  - 5.11.3 Heilongjiang Qingfengyuan Biological Engineering Technology Co., Ltd
  - 5.11.4 Liaoning Satellite Institute of Biological Products Co., Ltd.
  - 5.11.5 Shanghai Chemo Wanbang Biopharma Co., Ltd
  - 5.11.6 Changchun Heber Biological Technology Co., Ltd
  - 5.11.7 Shanghai Huaxin High Biotechnology Inc.

### **6 Major Foreign Companies**

- 6.1 Roche
  - 6.1.1 Profile
  - 6.1.2 Operation
  - 6.1.3 Revenue Structure
  - 6.1.4 Interferon Business
  - 6.1.5 Development in China
- 6.2 MSD
  - 6.2.1 Profile
  - 6.2.2 Operation
  - 6.2.3 Revenue Structure
  - 6.2.4 Interferon Business
  - 6.2.5 Development in China

### **7 Summary and Forecast**

- Classification and Characteristics of Interferon
- Development Course of Interferon Drugs
- Market Size of Chinese Medicine for Liver Disease Treatment, 2010-2016
- Market Structure of Chinese Medicine for Liver Disease Treatment, 2015
- Interferon Revenue and YoY Growth Rate of Chinese Sample Hospitals, 2012-2016
- Interferon Revenue of Chinese Sample Hospitals (by Type), 2012-2016
- Interferon Revenue of Chinese Sample Hospitals (by Product), 2012-2016
- China's Interferon Market Size, 2012-2016
- China's Interferon Market Structure (by Type), 2013-2016
- China's Interferon Market Structure (by Product), 2013-2016
- Market Share in China Interferon Industry (by Company), 2015
- Market Share in China Interferon Industry (by Company), 2016
- Ordinary Interferon Revenue of Chinese Sample Hospitals, 2012-2016
- China's Ordinary Interferon Market Size, 2012-2016
- Ordinary Interferon Market Share in China (by Company), 2015
- Product Specifications and the Latest Bid Prices of Major Ordinary Interferon Enterprises in China
- Registration and Approval of Long-acting Interferon in China
- Long-acting Interferon Revenue of Chinese Sample Hospitals, 2012-2016
- Long-acting Interferon Revenue of Chinese Sample Hospitals (by Product), 2012-2016
- China's Long-acting Interferon Market Size, 2012-2016
- Long-acting Interferon Revenue of Chinese Sample Hospitals (by Company), 2012-2016
- China's Long-acting Interferon Market Share (by Company), 2012-2016
- Major Long-acting Interferon R & D Enterprises in China and Their Product R & D Progress, 2016
- Product Specifications and Bid Prices of Long-acting Interferon Enterprises in China, 2016
- Market Size of Anti-Hepatitis B Virus Drugs in China, 2013-2016



- Major Drugs for Hepatitis B Treatment and Their Function in China
- Comparison between Main Nucleoside Drugs in China
- Share of Hepatitis B Antiviral Drugs in Chinese Sample Hospitals, 2010-2016
- China's Hepatitis B-use Interferon Market Size, 2013-2016
- China's Annual Hepatitis C Incidence, 2008-2016
- Development Course of Anti-Hepatitis C Drugs
- Launched New-type Anti-Hepatitis C Drugs Worldwide, 2013-2016
- Main New-type Anti-Hepatitis C Drugs in Research Worldwide, 2016
- Application for New-type Anti-Hepatitis C Drugs in China, 2016
- China's AIDS Incidence, 2011-2016
- China's AIDS Death Toll, 2011-2016
- Development Course of Anke Biotechnology
- Revenue and Net Income of Anke Biotechnology, 2013-2016
- Revenue of Anke Biotechnology (by Product), 2013-2016
- Revenue Structure of Anke Biotechnology (by Product), 2013-2016
- R & D Costs and % of Total Revenue of Anke Biotechnology, 2013-2016
- Interferon Products of Anke Biotechnology
- Interferon Product Specifications of Anke Biotechnology
- Interferon Revenue of Anke Biotechnology, 2013-2016
- Revenue and Net Income of Anke Biotechnology, 2016-2021E
- Revenue and Net Income of Tri-Prime Gene, 2013-2016
- R & D Costs of Tri-Prime Gene, 2013-2016
- Revenue of Tri-Prime Gene from Top 5 Clients, 2014-2016
- Interferon Product Specifications of Tri-Prime Gene
- Revenue and Net Income of Tri-Prime Gene, 2015-2021E

- Revenue and Net Income of Kawin Technology, 2013-2015
- Revenue Structure of Kawin Technology (by Product), 2013-2015
- Ongoing Research Projects and Progress of Kawin Technology
- R & D Costs of Kawin Technology, 2013-2015
- Fund-raising Investment Projects of Kawin Technology
- Revenue of Kawin Technology from Top 5 Clients, 2013-2015
- Main Interferon Products of Kawin Technology
- Interferon Product Specifications of Kawin Technology
- Interferon Revenue of Kawin Technology, 2013-2015
- Interferon Revenue of Kawin Technology (by Product), 2013-2015
- Revenue and Net Income of Kawin Technology, 2015-2021E
- Development Course of Amoytop Biotech
- Financial Data of Amoytop Biotech, 2013-2016
- Introduction to Amoytop Biotech's "Paigebin" Long-acting Interferon
- Development Course of Amoytop Biotech's "Paigebin" Long-acting Interferon
- Introduction to Shenzhen Kexing Biotech's "Sairuojin" Interferon
- Interferon Products of Sinobioway Biomedicine
- Interferon Product Specifications of Sinobioway Biomedicine
- 3SBio's Revenue and Net Income, 2014-2016
- 3SBio's Interferon Product Specifications
- Revenue and Net Income of Harbin Pharmaceutical Group Bioengineering, 2014-2016
- Main Interferon Products of Harbin Pharmaceutical Group Bioengineering
- Interferon Product Specifications of Harbin Pharmaceutical Group Bioengineering
- Interferon Product Specifications of Changchun Institute of Biological Products Co., Ltd.
- Interferon Product Specifications of Zhejiang Hansheng Pharmaceutical Co., Ltd. of Beisheng Pharma

- Interferon Product Specifications of Hainan Xinmingda Biopharmaceutical Co., Ltd
- Interferon Product Specifications of Beijing Yuance Pharmaceutical Co., Ltd.
- Interferon Product Specifications of Heilongjiang Qingfengyuan Biological Engineering Technology Co., Ltd
- Interferon Product Specifications of Liaoning Satellite Institute Of Biological Products Co., Ltd.
- Interferon Product Specifications of Shanghai Chemo Wanbang Biopharma Co., Ltd
- Interferon Product Specifications of Changchun Heber Biological Technology Co., Ltd
- Revenue and Net Income of Roche, 2013-2016
- Revenue Breakdown of Roche (by Division), 2013-2016
- Revenue Structure of Roche (by Division), 2013-2016
- Revenue Breakdown of Roche's Pharma Division (by Region), 2013-2016
- Revenue Structure of Roche's Pharma Division (by Region), 2013-2016
- Revenue Breakdown of Roche's Diagnosis Division (by Business), 2013-2016
- Revenue Structure of Roche's Diagnosis Division (by Business), 2013-2016
- Roche's Pegasys Revenue and % of Total Revenue, 2013-2016
- Roche's Pegasys Revenue (by Region), 2013-2015
- Roche's Pegasys Sales in Chinese Sample Hospitals, 2013-2016
- Revenue and Net Income of MSD, 2013-2016
- Revenue Breakdown of MSD (by Product), 2013-2016
- Revenue Structure of MSD (by Product), 2013-2016
- Revenue Breakdown of MSD (by Region), 2013-2016
- Revenue Structure of MSD (by Region), 2013-2016
- MSD's Peg-Intron Revenue and % of Total Revenue, 2013-2015
- MSD's Peg-Intron Sales in Chinese Sample Hospitals, 2012-2016
- China Interferon Market Size, 2016-2021E
- R&D of Key Long-acting Interferon in China, 2016

You can place your order in the following alternative ways:

1. Order online at [www.researchinchina.com](http://www.researchinchina.com)
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: [report@researchinchina.com](mailto:report@researchinchina.com)
4. Phone us at +86 10 82600828/ 82601561

<b>Party A:</b>			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

<b>Party B:</b>			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	<a href="mailto:report@researchinchina.com">report@researchinchina.com</a>	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
<i>Total</i>		

Choose type of format

- PDF (Single user license) .....2,400 USD
- Hard copy ..... 2,600 USD
- PDF (Enterprisewide license)..... 3,800 USD

※ Reports will be dispatched immediately once full payment has been received.  
Payment may be made by wire transfer or credit card via PayPal.

### About ResearchInChina

ResearchInChina ([www.researchinchina.com](http://www.researchinchina.com)) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

#### Our Major Activities

- *Multi-users market reports*
- *Database-RICDB*
- *Custom Research*
- *Company Search*

**RICDB** (<http://www.researchinchina.com/data/database.html>), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at [www.researchinchina.com](http://www.researchinchina.com)

For any problems, please contact our service team at: